Sign up to save your podcasts
Or
Share NEJM Interview: Lauren Jatt on the efficacy of twice-yearly lenacapavir for preexposure prophylaxis and its implications for the development of an HIV vaccine.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NEJM Interview: Lauren Jatt on the efficacy of twice-yearly lenacapavir for preexposure prophylaxis and its implications for the development of an HIV vaccine.
Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.
View all episodes
By NEJM Group
4.4
120120 ratings
Lauren Jatt is an infectious diseases fellow at the University of Washington. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. L.P. Jatt and Others. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant? N Engl J Med 2025;392:1561-1563.
More shows like NEJM Interviews
View all
JAMA Editors' Summary
128 Listeners
Medicine and Science from The BMJ
39 Listeners
NEJM Journal Watch Podcasts: Clinical Conversations
56 Listeners
NEJM This Week
318 Listeners
JACC Podcast
160 Listeners
JAMA Clinical Reviews
480 Listeners
Mayo Clinic Talks
283 Listeners
JAMA Medical News
91 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
136 Listeners
Leadership Conversations
5 Listeners
Core IM | Internal Medicine Podcast
1,094 Listeners
Curbside Consults
89 Listeners
Annals On Call Podcast
174 Listeners
The Clinical Problem Solvers
512 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
The Curious Clinicians
363 Listeners
Infectious Disease Puscast
78 Listeners
NEJM AI Grand Rounds
50 Listeners
Intention to Treat
30 Listeners
Not Otherwise Specified
45 Listeners